Last Updated : April 3, 2025
Details
FilesGeneric Name:
trametinib
Project Status:
Complete
Therapeutic Area:
Gynecological cancers
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0372-000
Call for patient/clinician input closed:
NOC Status at Filing:
N/A
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
For recurrent low-grade
serous ovarian cancer
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation/Report:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Submission received | September 06, 2024 |
|---|---|
| Review initiated | September 09, 2024 |
| Expert committee meeting (initial) | January 30, 2025 |
| Draft recommendation posted for stakeholder feedback | February 20, 2025 |
| End of feedback period | March 06, 2025 |
| Final recommendation posted | April 01, 2025 |
| CDA-AMC review report(s) posted | March 13, 2025 |
Files
Last Updated : April 3, 2025